SamanTree Medical Achieves FDA Clearance for Histolog® Scanner, Ushering in a New Era of Tissue Imaging in the U.S.
13.9.2024 09:00:00 EEST | Business Wire | Press release
SamanTree Medical, a leader in innovative surgical imaging solutions, today announced that it has received FDA 510(k) clearance of its Histolog® Scanner for imaging of the internal microstructure of tissues including, but not limited to, the identification of cells, vessels and their organization or architecture. This groundbreaking Swiss made device is designed to provide real-time, highresolution imaging of fresh tissue surfaces, offering surgeons and pathologists this information for excised tissue.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240912995435/en/
The Histolog Scanner in use for rapid visualization of fresh tissue microstructures. (Photo: SamanTree Medical)
The Histolog® Scanner enables real-time, ultra-fast confocal microscopy, allowing for the immediate imaging of resected tissues. This advancement aims to enable physicians to improve their efficiency.
“We are thrilled to introduce the Histolog® Scanner to the U.S. market,” said Dr. Charles Carignan, Executive Chairman of SamanTree Medical. “This FDA clearance is a significant milestone for the company. The ability of the Histolog® Scanner to produce real-time imaging of the internal microstructure of tissues provides surgeons and pathologists with immediate, actionable information.”
Prof. Dr. Alex Mottrie, Head of the Urological Department OLV Hospital, Aalst, Belgium and CEO of ORSI Academy, Ghent, Belgium, commented on the impact of this new technology: “The Histolog® Scanner represents cutting-edge technology in imaging of freshly excised tissue. Its ability to provide high-resolution, real-time images allows us to make more informed decisions.”
Prof. Dr. Ari D. Brooks, Director of Endocrine and Oncologic Surgery, Pennsylvania Hospital, Philadelphia, PA said “The Histolog technology has the potential to significantly reduce the cost, resources and delays associated with the current lack of real-time high-resolution imaging”. Prof Dr. Douglas Scherr, Clinical Director of Urologic Oncology at the Weill Medical College of Cornell University said “Providing imaging data at this resolution has the potential to aid in patient care. In our practice and across Urology, as a field, we are facing limitations in the ability to provide timely decisions to our patients. We will count on the Histolog Scanner to provide us with the ability to image the tissues’ microstructures in real-time and to enable us to make immediate decisions.”
The FDA clearance of the Histolog® Scanner marks a crucial moment in SamanTree Medical’s mission to expand its innovative imaging solutions globally. With this clearance, SamanTree is set to accelerate its U.S. market entry, ensuring that more healthcare providers can leverage the benefits of this cutting-edge technology.
About SamanTree Medical
SamanTree Medical is committed to enhancing clinical outcomes through the development of advanced imaging technologies. The Histolog® Scanner, now FDA-cleared, offers realtime, high-resolution imaging of excised tissue surfaces, providing physicians with this information for immediate assessments. Following the initial commercialization in Europe, the Histolog® Scanner is poised to make a significant impact in the U.S. healthcare market.
For more information, visit www.samantree.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912995435/en/
Contacts
Contact Information
Olivier Delporte
CEO, SamanTree Medical
info@samantree.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Adds Collaborating Firm Smartbridge16.7.2026 16:30:00 EEST | Press release
Andersen Consulting announces a Collaboration Agreement with Smartbridge, a Texas-based digital and AI technology firm, enhancing its capabilities in data and analytics, and digital transformation services. Founded in 2003, Smartbridge helps organizations accelerate their digital transformation and modernize operations through digital innovation, AI, data and analytics, and application modernization services. The firm works with clients in the oil and gas, medtech, and restaurant industries, combining advisory and technology services to enable enterprise transformation and growth. Leveraging strategic relationships with leading technology providers, Smartbridge helps organizations connect data, improve decision-making, and accelerate business outcomes. “Organizations today are looking to accelerate their digital and AI transformation and are searching for practical ways to translate innovation into measurable business value,” said Sri Raju, CEO of Smartbridge. “Our team focuses on help
Cyclic Materials Appoints Tomasz Poznar as Chief Commercial Officer to Accelerate Global Commercial Growth16.7.2026 16:20:00 EEST | Press release
Cyclic Materials, the rare earth recycling company building a circular supply chain for rare earth elements and critical materials, today announced the appointment of Tomasz Poznar, Ph.D., as Chief Commercial Officer. The appointment strengthens Cyclic Materials’ executive team as the company accelerates commercial expansion across North America, Europe, and Asia. Most recently, Poznar served as Chief Commercial Officer at Ascend Elements, where he led the company’s global commercial strategy, strategic partnerships, and business development. During his tenure, he helped secure more than USD $1.5 billion in commercial agreements, including a landmark USD $1 billion supply agreement with a major global automaker, while also supporting approximately USD $320 million in TCTF government funding that accelerated the company’s growth in North America and Europe. Prior to Ascend Elements, Poznar held leadership and engineering positions at A123 Systems, EnerDel, Delco Remy, and Volvo, where h
Modon Holding and Nammos Hotels & Resorts Bring Nammos Ras El Hekma to Egypt’s North Coast16.7.2026 15:50:00 EEST | Press release
Abu Dhabi-based Modon Holding and Nammos Hotels & Resorts have announced Nammos Ras El Hekma – the renowned lifestyle and hospitality brand’s first fully integrated destination in Egypt. Located within the Wadi Yemm precinct, the development will bring Ras El Hekma’s promise of timeless Mediterranean living to life, combining Nammos Residences, Nammos Resort, Nammos Village, and a curated selection of all-day dining and wellness experiences, including the globally renowned Nammos Restaurant & Beach Club. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716740934/en/ Modon Holding and Nammos Hotels & Resorts bring Nammos Ras El Hekma to Egypt’s North Coast (Photo: AETOSWire) Nammos Ras El Hekma represents a new expression of contemporary Mediterranean luxury. Reflecting both the natural beauty of Egypt’s North Coast and the refined yet vibrant lifestyle associated with Nammos, the destination introduces a lifestyle concept i
Crown Bioscience Joins C-Path's NAMs Developer Coalition to Advance Human-Relevant Models in Drug Development16.7.2026 15:30:00 EEST | Press release
Crown Bioscience is a global contract research organization (CRO) specializing in oncology drug discovery and development, today announced it has joined Critical Path Institute's (C-Path) New Approach Methodologies Developer Coalition (NAMs-DC), a collaborative initiative dedicated to advancing the validation, qualification and regulatory adoption of innovative human-relevant research methods. Crown Bioscience joins a growing community of technology developers, pharmaceutical companies, regulatory stakeholders and scientific experts working to accelerate the adoption of New Approach Methodologies (NAMs) across drug discovery and development. Through its participation in NAMs-DC, Crown Bioscience will contribute expertise spanning patient-derived xenograft (PDX) models, patient-derived tumor organoids, ex vivo patient tissue platforms, translational biomarker analysis and bioinformatics. The company is also expanding its capabilities across organoid-based toxicology, organ-on-chip colla
Tridiagonal.ai (T.AI) Partners with PETRONAS Carigali’s TriCipta AI with IBM to Advance Engineering Domain-Driven AI Solutions for Upstream Operations16.7.2026 15:30:00 EEST | Press release
Tridiagonal.ai Pvt. Ltd. (T.AI), the dedicated AI arm of Tridiagonal Group, announced its role in the third Joint Development Agreement (JDA) involving PETRONAS Carigali Sdn. Bhd. and IBM Malaysia Sdn. Bhd. to advance PETRONAS Carigali’s flagship TriCipta AI across the Upstream value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715579933/en/ Signing ceremony for the third TriCipta AI Joint Development Agreement, attended by executives from Tridiagonal.ai (T.AI), PETRONAS Carigali, and IBM Malaysia. TriCipta AI is PETRONAS Carigali’s partnership model that combines deep domain technical expertise with advanced AI technology experts to accelerate the development and deployment of upstream AI solutions. Through this collaboration, Tridiagonal.ai’s engineering domain-driven AI solutions will support upstream capabilities for Surface Equipment Optimisation with AI. The initiative focuses on production optimisation, ma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom